{"title":"Blocking Fpr3 ameliorates osteoarthritis by inhibiting NLRP3-mediated chondrocyte pyroptosis","authors":"Bin Zhou, Yaobin Huang","doi":"10.1016/j.cyto.2025.157020","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Osteoarthritis (OA) is a chronic joint disorder that frequently diagnosed in elderly individuals. While formyl peptide receptor 3 (Fpr3) is known to play a significant role in inflammation, its involvement in OA progression and chondrocyte pyroptosis remains unclear.</div></div><div><h3>Methods</h3><div>Anterior cruciate ligament transection (ACLT) was used to create OA mouse model. Lipopolysaccharide (LPS) was utilized to induce inflammation in chondrocytes. We assessed the expression of Fpr3, chondrogenic markers (Collagen-II, SOX9, and Aggrecan), catabolic factors (MMP3, MMP13, and ADAMTS5), inflammatory cytokines (IL-1β, IL-18, and COX-2), and NLRP3 inflammasome members (NLRP3, ASC, Cleaved caspase1, and GSDMD-N) in cartilage from ACLT-induced mouse models and LPS-treated chondrocytes.</div></div><div><h3>Results</h3><div>Fpr3 expression was significantly increased in both ACLT-induced OA mice and LPS-induced chondrocytes. Fpr3 knockdown reduced chondrocyte injury in OA mice. Fpr3 knockdown promoted the expression of collagen-II, SOX9, and aggrecan, while suppressing the expression of MMP3, MMP13, ADAMTS5, IL-1β, IL-18, COX-2, NLRP3, ASC, cleaved caspase1, and GSDMD-N in both experimental models.</div></div><div><h3>Conclusions</h3><div>Blocking Fpr3 ameliorated extracellular matrix degradation and pyroptosis during OA progress through the NLRP3 inflammasome. Modulating Fpr3 expression may be a therapeutic target for OA.</div></div>","PeriodicalId":297,"journal":{"name":"Cytokine","volume":"195 ","pages":"Article 157020"},"PeriodicalIF":3.7000,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytokine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S104346662500167X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
Osteoarthritis (OA) is a chronic joint disorder that frequently diagnosed in elderly individuals. While formyl peptide receptor 3 (Fpr3) is known to play a significant role in inflammation, its involvement in OA progression and chondrocyte pyroptosis remains unclear.
Methods
Anterior cruciate ligament transection (ACLT) was used to create OA mouse model. Lipopolysaccharide (LPS) was utilized to induce inflammation in chondrocytes. We assessed the expression of Fpr3, chondrogenic markers (Collagen-II, SOX9, and Aggrecan), catabolic factors (MMP3, MMP13, and ADAMTS5), inflammatory cytokines (IL-1β, IL-18, and COX-2), and NLRP3 inflammasome members (NLRP3, ASC, Cleaved caspase1, and GSDMD-N) in cartilage from ACLT-induced mouse models and LPS-treated chondrocytes.
Results
Fpr3 expression was significantly increased in both ACLT-induced OA mice and LPS-induced chondrocytes. Fpr3 knockdown reduced chondrocyte injury in OA mice. Fpr3 knockdown promoted the expression of collagen-II, SOX9, and aggrecan, while suppressing the expression of MMP3, MMP13, ADAMTS5, IL-1β, IL-18, COX-2, NLRP3, ASC, cleaved caspase1, and GSDMD-N in both experimental models.
Conclusions
Blocking Fpr3 ameliorated extracellular matrix degradation and pyroptosis during OA progress through the NLRP3 inflammasome. Modulating Fpr3 expression may be a therapeutic target for OA.
期刊介绍:
The journal Cytokine has an open access mirror journal Cytokine: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review.
* Devoted exclusively to the study of the molecular biology, genetics, biochemistry, immunology, genome-wide association studies, pathobiology, diagnostic and clinical applications of all known interleukins, hematopoietic factors, growth factors, cytotoxins, interferons, new cytokines, and chemokines, Cytokine provides comprehensive coverage of cytokines and their mechanisms of actions, 12 times a year by publishing original high quality refereed scientific papers from prominent investigators in both the academic and industrial sectors.
We will publish 3 major types of manuscripts:
1) Original manuscripts describing research results.
2) Basic and clinical reviews describing cytokine actions and regulation.
3) Short commentaries/perspectives on recently published aspects of cytokines, pathogenesis and clinical results.